HomeHealth articlesspinal muscle atrophyWhat Is the Respiratory Management of Spinal Muscular Atrophy?

Respiratory Management of Spinal Muscular Atrophy

Verified dataVerified data
0

4 min read

Share

Respiratory involvement in spinal muscular atrophy leads to a series of events resulting in respiratory failure. Read the article below to know more.

Medically reviewed by

Dr. Kaushal Bhavsar

Published At March 29, 2023
Reviewed AtMarch 29, 2023

Introduction

Spinal muscular atrophy is a common neuromuscular disorder that causes bilateral weakness and atrophy of the proximal muscles. The respiratory muscles are the intercostal muscles, and the diaphragm is relatively spared. As a result of the muscle weakness and atrophy, the affected patient has impaired cough reflex, and the airway secretions are not cleared, which translates into recurrent respiratory infections, poor chest wall, and lung growth, which will lead to restrictive lung disease (decline in the total volume of air that the lungs can hold), nocturnal hypoventilation (shallow breathing at night, occurs as a complication of neuro-muscular disorders) and eventually into respiratory failure.

How Is Respiratory Function Monitored?

Systematic monitoring of respiratory muscle function is necessary for patients with spinal muscular atrophy to foresee any respiratory complications, like respiratory failure, and provide appropriate clinical care accordingly.

Systematic monitoring is done in a clinical setup with non-invasive procedures, such as:

  • Vital capacity (the maximum amount of air one can expire after maximum air intake).

  • Peak expiratory flow (maxim speed with which air is expired).

  • Maximal static pressure (the measurement of maximum mouth pressure against an occluded airway).

  • Sniff nasal inspiratory pressure (pressure measured through an occluded nostril while sniffing through the other nostril).

  • Peak cough flow (it is the maximum airflow during a cough).

All the procedures mentioned above are simple and easily available, thus, are commonly used. In young children, invasive tests are employed to check for the performance of respiratory muscles because of poor cooperation and extreme respiratory muscle weakness. For detecting nocturnal hypoventilation, sleep studies are performed, and nocturnal gas exchange is monitored overnight. When the strength of respiratory muscles falls below 50 % or if the patient suffers from repeated respiratory infections, training is given for assisting cough so that the secretions are expectorated from the airways. Non-invasive ventilation (NIV) should be established in children with isolated cases of nocturnal hypoventilation. Pediatric management of respiratory involvement in spinal muscular atrophy involves a multidisciplinary (respiratory and neurology) approach for the best care of children.

What Is Spinal Muscular Atrophy (SMA)?

Spinal Muscular Atrophy is a common neuromuscular disorder characterized by a progressive decline in motor function. The incidence of SMA is one in 6000 to one in 10,000 live births and is the leading cause of mortality in toddlers due to genetic reasons. It is associated with muscle weakness and atrophy that results from the progressive destruction of specialized neurons that controls voluntary movements. SMA is divided into five major types based on the age when the symptoms begin to appear; they are:

  • Type 0.

  • Type 1.

  • Type 2.

  • Type 3.

  • Type 4.

Of these, type 0 is the most severe form, with the onset of disease before birth, and type 4, is the mildest form, where the symptoms appear in adulthood only.

How Does Spinal Muscular Atrophy Affect the Respiratory System?

Spinal muscular atrophy types 0, 1, and 2 are commonly associated with severe respiratory problems in children and are the main cause of morbidity and mortality among children with these disease types.

  • SMA affects the intercoastal muscles and results in their weakness and atrophy, leaving the diaphragm to manage the role of the main breathing muscle single-handedly. As a result, the patient will have difficulty in breathing. The lung and the chest wall will be underdeveloped, and a restrictive lung will be prone to recurrent and severe respiratory infections. Due to weakness in the muscle, the cough reflex will be poor, accumulating secretions from the airways, increasing the risk of infection and hypoventilation.

  • Muscle weakness will also lead to another serious complication known as aspiration pneumonia. It is a lung infection that occurs due to the entry of food or liquid into the lungs because of the poor coordination of deglutition with the closure of the airway as a result of throat muscle weakness.

  • Hypoventilation and difficulty in breathing worsen at night. When a patient lies down, most muscles will relax, and the contents in the abdomen are pushed up against the diaphragm. Since the diaphragm acts as the main breathing muscle in SMA, the patient will face additional difficulty taking deep breaths when lying down, which may lead to sleeping difficulties, such as obstructive sleep apnea.

How to Manage Respiratory Concerns in Spinal Muscular Atrophy (SMA)?

  • Respiratory muscle weakness and atrophy are significant problems in SMA. It is the commonest cause of mortality in SMA types 0,1 and 2 but not the only cause. Due to respiratory muscle weakness, air movement into and out of the lungs does not occur smoothly and results in general adverse health. Respiratory muscle weakness will display signs such as headaches, insomnia, tiredness, and frequent yawning in the daytime due to sleep deprivation, poor concentration, difficulty lying down flat, lung infections, and eventually respiratory failure and heart damage.

  • Appropriate ventilation is required for an SMA patient with respiratory muscle weakness. The invention of portable ventilation devices in recent years has made it easier for infants with SMA and has helped extend life to a great extent for some. Assisted ventilation is also used in various SMA forms in children and adults.

  • Invasive procedures are used when sufficient ventilation is not feasible through non-invasive techniques. Tracheostomy is one such procedure to assist in ventilation. In this procedure, a surgical hole is created in the trachea, or the windpipe, and a tube are inserted through which air is delivered under pressure. Once the patient gets adapted to the tracheostomy tube, they can talk, eat and drink comfortably with the tube.

  • Another thing that needs to be taken care of is the excess secretions in the respiratory passage; they need to be cleared with a mechanical device to prevent the onset of infections. One such device is an insufflator- that will help clear the secretions from the airway, mimicking a natural cough mechanism. It first creates a positive pressure in the airway and then immediately reverses to negative pressure expectorating the secretions. A high-frequency Chest Wall Oscillation Device is another mechanical clearance aid. It is made up of a vest worn around the chest that inflates and deflates rapidly. It will create vibrations in the chest resulting in mini coughs, which will help expectorate the secretions.

Conclusion

Respiratory involvement in spinal muscular dystrophy plays an important role in morbidity and mortality in children. A multidisciplinary pediatric approach involving a team of pulmonologists, neurologists, physiotherapists, and experienced home non-invasive ventilation (NIV) assistance is necessary to obtain optimal respiratory care. A regular and systematic evaluation of the functioning of respiratory muscles is crucial for effectively managing possible respiratory complications.

Frequently Asked Questions

1.

What Does Respiratory Support Entail in the Case of SMA?

In the case of SMA (Spinal Muscular Atrophy), respiratory support involves assisting individuals with weakened breathing muscles to help them maintain proper lung function and adequate breathing. This can encompass various interventions and strategies, including using devices, techniques, and therapies to optimize respiratory health and overall well-being.

2.

What Respiratory Complications Can Arise From SMA?

Respiratory complications stemming from SMA (Spinal Muscular Atrophy) can include weakened breathing muscles, difficulty coughing, ineffective airway clearance, and, in severe cases, respiratory failure. These issues arise from the progressive muscle weakness caused by SMA, leading to proper lung function and ventilation challenges.

3.

How Is Spinal Muscular Atrophy Treated?

SMA treatment includes disease-modifying therapies like Spinraza, Zolgensma, and Risdiplam to boost SMN protein levels. Supportive care manages breathing, nutrition, and mobility. Multidisciplinary teams provide comprehensive care while clinical trials explore new treatments. Family support, education, and early intervention enhance the quality of life.

4.

What Constitutes the Basics of Respiratory Support?

Respiratory support basics for SMA involve devices like Bilevel Positive Airway Pressure (BiPAP) and continuous Positive Airway Pressure (CPAP) They are used to provide pressurized air to the airways and cough assist helps to simulate a cough by delivering a burst of air at high pressure followed by a drop in pressure. In severe cases, mechanical ventilation might be needed. The goal is to maintain lung function and prevent complications.

5.

What Precautions Are Recommended for Individuals With Spinal Muscular Atrophy?

Individuals with Spinal Muscular Atrophy (SMA) should take precautions tailored to their condition. Prioritizing respiratory care through prescribed devices like BiPAP, CPAP, and cough assist is crucial. Engaging in appropriate physical activity while being cautious not to overexert is important. A balanced diet, hydration, and well-maintained seating and posture support overall health. Regular medical follow-ups, infection prevention, and good respiratory hygiene are advised. Emergency plans, emotional support, adaptive equipment, and proper medication management contribute to a well-rounded approach to managing SMA. 

6.

What Respiratory Challenges Are Associated With SMA Type 1?

The respiratory challenges associated with SMA Type 1:
- Weak Breathing Muscles: Severe muscle weakness affects respiratory muscles.
- Inefficient Cough: Difficulty clearing mucus due to weak coughing ability.
- Reduced Lung Capacity: Muscular weakness leads to shallow breathing and limited lung expansion.
- Respiratory Failure: Weak muscles and reduced lung function can cause breathing difficulties.
- Dependence on Support: This often requires continuous respiratory support like NIV or mechanical ventilation.
- Infection Susceptibility: A weakened respiratory system increases the risk of infections.
- Respiratory Complications: Frequent hospitalizations due to respiratory distress and infections.
- Early Intervention: Early intervention is vital for managing symptoms and improving quality of life.

7.

Which Drugs Have Been Granted Approval for the Treatment of Spinal Muscular Atrophy?

The approved drugs for Spinal Muscular Atrophy (SMA) treatment are:
- Nusinersen (Spinraza): Increases functional SMN protein through intrathecal injection.
- Onasemnogene Abeparvovec (Zolgensma): Provides a functional SMN1 gene via a one-time infusion, mainly for SMA Type 1.
- Risdiplam: Boosts SMN protein production orally, used for Types 1, 2, and 3.

8.

What Is the Initial Oral Medication for Addressing Spinal Muscular Atrophy in Patients?

The initial oral medication used to address Spinal Muscular Atrophy (SMA) in patients is Risdiplam.  It is an orally administered medication that targets the SMN2 gene to increase the production of the survival motor neuron (SMN) protein, which is deficient in SMA patients. Evrysdi is a brand name for the drug Risdiplam.

9.

What Is the Name of the Injectable Treatment for SMA?

The injectable treatment for Spinal Muscular Atrophy (SMA) is called "Spinraza." It is known by the brand name "Spinraza" and contains the drug nusinersen. This medication treats SMA, a genetic disorder impacting spinal cord motor neurons, causing muscle weakness and atrophy. The administration of Spinraza is done through intrathecal injection, which means it is injected directly into the cerebrospinal fluid surrounding the spinal cord. This treatment aims to increase the production of the survival motor neuron (SMN) protein in individuals with SMA. 

10.

How Is Spinal Muscular Atrophy Typically Managed?

Here is a concise list of how Spinal Muscular Atrophy (SMA) is typically managed:
- Medications: Drugs like Spinraza and Evrysdi aim to boost survival motor neuron (SMN) protein production.
- Therapy: Physical and occupational therapy maintain muscle strength and mobility.
- Respiratory Care: Breathing support, devices, and monitoring prevent respiratory issues.
- Nutrition: Specialized diets and assistance maintain proper nutrition.
- Orthopedic Care: Bracing and surgeries address muscle-related skeletal and joint problems.
- Psychosocial Support: Counseling and support groups aid emotional well-being.
- Medical Monitoring: Regular assessments track disease progression.
- Education: Educational support and accommodations for children with SMA.
- Genetic Counseling: Provides information about SMA inheritance and family planning.
- Clinical Trials: Participation can offer access to emerging treatments.

11.

What Potential Future Therapies Are Being Explored for SMA?

Some of the future therapies for SMA are as follows:
- Gene Replacement Therapy: Introducing a functional SMN1 gene into cells.
- Gene Editing: Correcting mutated SMN1 gene using techniques like CRISPR-Cas9.
- Antisense Oligonucleotides (ASOs): Targeting RNA to increase SMN protein production.
- Exon Skipping: Skipping specific gene sections to encourage better SMN protein creation.
- Small Molecule Therapies: Exploring drugs that enhance SMN protein levels.
- Combination Therapies: Mixing different treatments for potentially stronger effects.
- Muscle-Targeted Therapies: Directly addressing muscle function and resistance to atrophy.
- Neuroprotective Agents: Developing drugs to safeguard motor neurons from degeneration.
- Stem Cell Therapy: Investigating stem cells as SMN protein sources for transplantation.
- Neuromuscular Junction Stabilization: Enhancing nerve-muscle connections for improved function.
- Regulatory Approvals: Expanding existing treatments' availability to more patients.

12.

What Is the Typical Life Expectancy for Individuals With SMA?

The life expectancy for individuals with Spinal Muscular Atrophy (SMA) can vary widely depending on the type and severity of the condition.
Type 0: Most severe, typically leads to early infant mortality.
Type 1: Severe, improved with treatments, but life expectancy can still be limited.
Type 2: Milder, variable life expectancy, with improved care and treatments.
Type 3: Milder still, near-normal to slightly reduced life expectancy.
Type 4: Mildest form, normal life expectancy.

13.

What Is the Leading Cause of Mortality Among SMA Patients?

The primary cause of mortality among individuals with Spinal Muscular Atrophy (SMA), especially in severe types (Type 0, Type 1, and sometimes Type 2), is often respiratory complications due to weakened breathing muscles and vulnerability to infections like pneumonia.

14.

What Is the Estimated Cost of SMA Treatment?

The cost of Spinal Muscular Atrophy (SMA) treatment can vary based on factors like treatment type, location, and insurance coverage:
- Spinraza (Nusinersen): Can range from tens of thousands to hundreds of thousands of dollars per dose, requiring multiple doses.
- Evrysdi (Risdiplam): Typically oral and might be comparatively less expensive than Spinraza.
- Emerging Treatments: Costs vary based on treatment complexity.
- Supportive Care: Physical therapy, respiratory support, and devices also contribute to costs.
- Factors Affecting Cost: Healthcare policies, insurance coverage, and patient assistance programs.
Source Article IclonSourcesSource Article Arrow
Dr. Kaushal Bhavsar
Dr. Kaushal Bhavsar

Pulmonology (Asthma Doctors)

Tags:

spinal muscle atrophy
Community Banner Mobile
By subscribing, I agree to iCliniq's Terms & Privacy Policy.

Source Article ArrowMost popular articles

Do you have a question on

spinal muscle atrophy

Ask a doctor online

*guaranteed answer within 4 hours

Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.

This website uses cookies to ensure you get the best experience on our website. iCliniq privacy policy